Met primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile of Velphoro® confirmed...

Topline data expected in the second half of 2021 St. Gallen, Switzerland, and Uniondale, NY, 29 April 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of...

CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is...

Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the first therapy available in Europe...

St. Gallen, Switzerland, 26 March 2021 – Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6...

FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVATM injection would be first therapy for treatment of pr uritus in hemodialysis patients...

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 Net sales up 3.7% at constant exchange rates (CER), despite significant...

Dr Alexandre LeBeaut to be proposed to Annual General Meeting for appointment to Board Dr Gianni Zampieriand Gilbert Achermann will not stand for re-election St. Gallen, Switzerland, 02 February 2021

As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from...

In its sixth year, a growing international coalition underlines significant harm to health caused by iron deficiency Impact on women moves up political agenda at REYKJAVÍK GLOBAL FORUM - WOMEN...